A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2017
At a glance
- Drugs MK 5160 (Primary) ; Glucose; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms MK-5160-002
- Sponsors Merck Sharp & Dohme
- 19 Dec 2017 Planned End Date changed from 8 Jan 2018 to 22 Jan 2018.
- 19 Dec 2017 Planned primary completion date changed from 8 Jan 2018 to 22 Jan 2018.
- 29 Nov 2017 Status changed from recruiting to active, no longer recruiting.